Alkem Laboratories shares fell 5% after Q4FY25 results showed a modest 4.2% profit rise to Rs 306 crore and margin contraction to 12.4%. While Jefferies downgraded the target to Rs 4,460 citing weak margins, Nomura maintained a ‘Buy’ with a Rs 5,430 target. The company expects high single-digit revenue growth in FY26 and rising tax rates in FY27.
Rate cuts unlikely in near term as inflation stays sticky: Richard Harris
Global market expert Richard Harris anticipates minimal changes to U.S. monetary policy, emphasizing the Fed’s independence. He notes that Big Tech’s recent profitability stems more